PDF icon Download PDF
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1810067
Case Report with Review of Literature

Endocervical Adenocarcinoma as a Secondary Malignancy in a Patient Treated for Non-Hodgkin's Lymphoma: A Case Report with Review of Literature

Garima Dhull
1   Department of Pathology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
,
Minakshi Bhardwaj
1   Department of Pathology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
,
Stuti Gupta
2   Department of Obstetrics & Gynecology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
,
Mukta Pujani
1   Department of Pathology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
,
Varsha Chauhan
1   Department of Pathology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
,
Neha Garg
1   Department of Pathology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
,
J.C Sharma
2   Department of Obstetrics & Gynecology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
,
Sunita Malik
2   Department of Obstetrics & Gynecology, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India
› Author Affiliations
Funding None.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Secondary malignancy can arise in patients with non-Hodgkin's lymphoma (NHL) on long follow-up. The risk of developing secondary malignancies is increased in NHL survivors, as compared to normal population and varies according to age, gender, and treatment modality. The nature of solid organ malignancy in order of frequency includes lung cancer followed by prostate, bladder, colon, breast, etc. Gynecological malignancy occurring in an NHL survivor is an extremely rare phenomenon with a low observed/expected ratio (0.89–0.93) as compared to other solid tumors. We hereby report a case of endocervical adenocarcinoma arising in a 51-year-old female patient who was a known treated case of NHL. This case highlights the fact that chemotherapy-induced atypia may mimic malignancy as well as the rare occurrence of gynecological cancers as a secondary malignancy in patients with NHL.

Keywords

secondary malignancy - NHL - endocervical adenocarcinoma - gynecological malignancy - case report

Patients' Consent

The authors confirm that all necessary patient consent forms have been obtained. The patient has provided written permission for their medical images and clinical details to be included in this publication. They have been informed that their identity will be protected by withholding their name and initials.




Publication History

Article published online:
10 July 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Parsons MW, Rock C, Chipman JJ. et al. Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med 2023; 12 (03) 2624-2636
    PubMedSearch in Google Scholar
  • 2 Moser O, Zimmermann M, Meyer U. et al. Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica 2021; 106 (05) 1390-1400
    PubMedSearch in Google Scholar
  • 3 Fleury I, Chevret S, Pfreundschuh M. et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol 2016; 27 (03) 390-397
    PubMedSearch in Google Scholar
  • 4 Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107 (01) 108-115
    PubMedSearch in Google Scholar
  • 5 Joelsson J, Wästerlid T, Rosenquist R. et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv 2022; 6 (08) 2657-2666
    PubMedSearch in Google Scholar
  • 6 Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 2011; 22 (08) 1845-1858
    PubMedSearch in Google Scholar
  • 7 Sacchi S, Marcheselli L, Bari A. et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93 (03) 398-404
    PubMedSearch in Google Scholar